Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis

Journal of Pathology

Volumn 184, Issue 1, 1998, Pages 53-57

  De Jong, Johannes S ^a   Van Diest, Paul J ^a   Van Der Valk, Paul ^a   Baak, Jan P A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; bFGF; Breast carcinoma; EGFR; Growth factor receptors; Growth factors; Mitosis; Neovascularization; PDGF; PDGF receptors; Proliferation; TGF ; TGF ; TGF receptor; VEGF; VEGF receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH INHIBITOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL DIVISION; FEMALE; GROWTH INHIBITORS; GROWTH SUBSTANCES; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PARACRINE COMMUNICATION; RECEPTORS, GROWTH FACTOR;

EID: 0031884413     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7     Document Type: Article

References (58)

1. Aaltomaa S, Lipponen P, Eskelinen M, et al. Prognostic factors in axillary lymph node-negative (pN - ) breast carcinomas. Eur J Cancer 1991; 27: 1555-1559.
2. Baak JPA, Dop H van, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374-382.
3. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991; 68: 1309-1317.
4. Diest PJ van, Baak JPA. The morphometric multivariate prognostic index (MPI) is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients. Hum Pathol 1992; 22: 479-489.
5. Linden JC van der, Baak JPA, Lindeman J, Hermans J, Meijer CJLM. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol 1987; 40: 302-306.
6. Uyterlinde AM, Schipper NW, Baak JPA, Peterse H, Matze P. Limited prognostic value of cellular DNA content to classical and morphological parameters in invasive ductal breast cancer. Am J Clin Pathol 1988; 89: 301-307.
7. Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 59: 943-947.
8. Sahin AA, Ro J, Ro JY, et al. Ki67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 1991; 68: 549-557.
9. Kamel OW, Franklin WA, Ringus JC, Meyes JS. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 1989; 134: 107-113.
10. Meyer JS, Friedman E, McCrate MM, Bauer WC. Prediction of early course of breast carcinoma by thymidine labeling. Cancer 1983; 51: 1879-1886.
11. Weidner N, Moore DH, Ljung BM, et al. Correlation of bromodeoxyuridine (BrdU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol 1993; 17: 987-994.
12. Joensuu H, Toikkanen S, Klemi PJ. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990; 66: 331-340.
13. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-1053.
14. Folkman J, Klagsbrun M. Tumor angiogenesis. Effect on tumor growth and immunity. In: Gottlieb A, Plescia OJ, Bishop DHL, eds. Fundamental Aspects of Neoplasia. New York: Springer-Verlag, 1975.
15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
16. Gomm JJ, Smith J, Ryall GK, Baillie R, Turnbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res 1991; 51: 4685-4692.
17. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992; 66: 273-280.
18. Peyrat JP, Bonneterre J, Hondermarck H, et al. Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer. J Steroid Biochem 1992; 43: 87-94.
19. Anan K, Morisaki T, Katano M, et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996; 119: 333-339.
20. Toi M, Yamamoto Y, Taniguchi T, Saji S, Hayashi K, Tominaga T. Regulation of endothelial growth factor expression in breast cancer. Jpn J Cancer Chem 1996; 23: 75-79.
21. Seymour L. Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Tr 1994; 32: 229-233.
22. Coltrera MP, Wang J, Porter PL, Gown AM. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Rec 1995; 55: 2703-2708.
23. Coombes RC, Barrett-Lee P, Luqmani Y. Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 1990; 37: 833-837.
24. Ro J, Ro JY, Brasfield F, Hortobagyi G, Blick M. SIS/PDGF-B expression in benign and malignant human breast lesions. Oncogene 1989; 4: 351-354.
25. Salomon DS, Zwiebel JA, Bano M. Presence of transforming growth factors in human breast cancer cells. Cancer Res 1984; 44: 4069-4077.
26. Macias A, Perez R, Hagenstrom T. Identification of transforming growth factor alpha in human primary breast carcinomas. Anticancer Res 1987; 7: 1271-1275.
27. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasari N. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I, and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 1990; 10: 1115-1126.
28. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, Sorvillo JM. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. Am J Pathol 1991; 138: 1527-1534.
29. Dublin EA, Barnes DM, Wang DY, King RJ, Levison DA. TGF alpha and TGF beta expression in mammary carcinoma. J Pathol 1993; 170: 15-22.
30. Castellani R, Visscher DW, Wykes S, Sarkar FH, Crissman JD. Interaction of transforming growth factor-alpha and epidermal growth factor receptor in breast carcinoma. An immunohistologic study. Cancer 1994; 73: 344-349.
31. Panico L, D'Antonio A, Salvatore G, et al. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996; 65: 51-56.
32. Brown LF, Berse B, Jackman RW. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
33. knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-428.
34. Murray PA, Barrett-Lee P, Travers M, Luqmani Y, Powels T, Coombes RC. The prognostic significance of transforming growth factors in human breast cancer. Br J Cancer 1993; 67: 1408-1412.
35. MacCullum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM, Miller WR. Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer 1994; 69: 1006-1009.
36. Auvinen P, Lipponen P, Johansson R, Syrjänen K. Prognostic significance of TGF-β1 and TGF-β2 expression in female breast cancer. Anticancer Res 1995; 15: 2627-2632.
37. Amoils KD, Seymour L, Bezwoda WR. Comparison between immunocytochemical and polymerase chain reaction techniques for detection of oestrogen receptor and transforming growth factor beta in breast cancer. Br J Cancer 1996; 73: 1255-1259.
38. Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; i: 1398-1402.
39. Lewis S, Locker A, Todd JH. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 1990; 143: 385-389.
40. Gasparini G, Bevilacqua P, Pozza F, et al. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 1992; 66: 970-976.
41. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptors, and other angiogenic factors in human cancer. Cancer Res 1996; 56: 2013-2016.
42. Jong JS de, Diest PJ van, Valk P van der, Baak JPA. Expression of growth factors, growth inhibiting factors and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 1998; 184: 44-52.
43. Bobrow MN, Litt GJ, Shaughnessy KJ, Mayer PC, Conlon J. The use of catalyzed reporter deposition as a means of signal amplification in a variety of formats. J Immunol Methods 1992; 150: 145-149.
44. Jong JS de, Diest PJ van, Baak JPA. Heterogeneity and reproducibility of microvessel counts in breast cancer: a methodological study. Lab Invest 1995; 76: 922-926.
45. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
46. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new, significant, and independent prognostic indicator in early staged breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887.
47. Gross JL, Herblin WF, Dusak BA, et al. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993; 85: 121-131.
48. Musgrove EA, Sutherland RL. Acute effect of growth factors on T-47D breast cancer cell cycle progression. Eur J Cancer 1993; 29A: 2273-2279.
49. Klijn JGM, Berns PMJJ, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3-17.
50. Roberts AB, Sporn NB. Transforming growth factor beta. Adv Cancer Res 1988; 51: 107-145.
51. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and their Receptors. Handbook of Experimental Pharmacology. Vol 95/1. Heidelberg: Springer-Verlag, 1990; 419-472.
52. Ueki N, Nakazato M, Ohkawa T, et al. Excessive production of TGFβ1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Act 1992; 1137: 189-196.
53. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
54. Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC. Transforming growth factor β1 induces angiogenesis in vivo with a threshold pattern. Lab Invest 1996; 74: 600-608.
55. Visscher DW, DeMattia F, Ottosen S, Sarkar FH, Crissman JD. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. Mod Pathol 1995; 8: 665-670.
56. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994: 85: 1045-1049.
57. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-761.
58. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454-466.